This inventor holds 2 USPTO granted patents. Top assignee: Astrazeneca Ab. Active years: 2006-2007.
Location History:
- Reims Cedex, FR (2006)
- Reims Cedex 2, FR (2007)
Company Filing History:
Years Active: 2006-2007
Title: Thomas Geoffrey Bird: Innovator in Pharmaceutical Chemistry
Introduction
Thomas Geoffrey Bird is a notable inventor based in Reims, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 2 patents, his work focuses on innovative solutions for medical challenges.
Latest Patents
Bird's latest patents include "Pyrazole derivatives as GnRH inhibitors." This invention relates to a group of novel thieno-pyrrole compounds that serve as gonadotrophin-releasing hormone antagonists. The patent also covers pharmaceutical formulations of these compounds, methods of treatment using them, and processes for their preparation. Another significant patent is for "Indole derivatives with vascular damaging activity." This invention provides a compound that is predicted to selectively destroy tumor vasculature, making it useful in inhibiting and alleviating symptoms associated with angiogenesis.
Career Highlights
Thomas Geoffrey Bird is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca focuses on the development of innovative therapies that address critical health issues. His contributions have been instrumental in advancing the company's research initiatives.
Collaborations
Bird has collaborated with notable colleagues in his field, including Francis Thomas Boyle and David Charles Blakey. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Thomas Geoffrey Bird is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in medical treatments. His patents reflect a commitment to addressing complex health challenges through innovative solutions.